A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

"Clinical study protocols may involve more than one PET [amyloid-beta] scan per patient,” the CMS announcement said.

PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam. 

This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients. 

The Society of Nuclear Medicine and Molecular Imaging has chosen its 2022 Image of the Year, and it’s one that is sure to interest anyone in the field of cardiac imaging.

Salvage radiation therapy guidelines for patients with prostate cancer recurrence need to be updated to include findings identified on PSMA PET, according to new research shared at SNMMI’s annual conference this week. 

“High-quality artificial intelligence-generated images preserve vital information from raw PET images without the additional radiation exposure from CT scans,” experts involved in the study explained.